ENvue Medical Inc
FEED
5 hedge funds and large institutions have $142K invested in ENvue Medical Inc in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 2 closing their positions.
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
0.01% less ownership
Funds ownership: 0.03% → 0.02% (-0.01%)
29% less funds holding
Funds holding: 7 → 5 (-2)
30% less capital invested
Capital invested by funds: $204K → $142K (-$61.5K)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
+$1.94K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$52.1K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$12.6K |
| 3 |
Bank of America
Charlotte,
North Carolina
|
-$389 |
FEED Hedge Fund Activity: Q2 2023 in Review
5 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in ENvue Medical Inc (FEED) for Q2 2023, worth a combined $142K — down 30% from $204K a quarter earlier.
Sellers outnumbered buyers: 2 funds closed out of FEED and 0 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 1 added.
The largest buyer was Tower Research Capital (TRC), adding an estimated $1.94K. The largest seller was Vanguard Group, cutting an estimated $52.1K.
- 5 institutional investors held ENvue Medical Inc (FEED) as of Q2 2023, down from 7 in Q1 2023.
- Funds reported $142K of ENvue Medical Inc stock for Q2 2023, down 30% quarter-over-quarter.
- 0 funds opened new ENvue Medical Inc positions in Q2 2023 and 2 closed out, a net change of -2 holders.
- The largest ENvue Medical Inc buyer in Q2 2023 was Tower Research Capital (TRC), an estimated $1.94K added.
- The largest ENvue Medical Inc seller in Q2 2023 was Vanguard Group, an estimated $52.1K sold.
Based on aggregated 13F filings for Q2 2023.